从项目暂停到新冠大流行:澳大利亚疫苗药物警戒系统十年定性评估
2010年澳大利亚因某品牌流感疫苗与发热和热性惊厥相关而暂停5岁以下儿童接种计划,后续国家审查提出七项建议。专家认为系统已有显著改进,尤其建立了主动队列事件监测系统,并对新冠疫苗安全监测有信心。
要点
- 2010年儿童流感疫苗因发热和热性惊厥关联被暂停,推动国家审查提出七项建议。
- 十年间澳大利亚疫苗药物警戒系统显著改进,建立了主动队列事件监测系统。
- 专家认为新冠免疫规划是完善主动监测与自发报告整合及数据链接的契机。
核心结论
- 澳大利亚疫苗安全专家对过去十年实施的创新药物警戒系统有信心。
- 新冠疫苗实施是加强现有系统并开发系统性疫苗药物警戒方法的机会。
研究设计与样本
- 访谈指南基于澳大利亚和国际关键框架,采用主题分析法和演绎法编码数据。
主要发现
- 访谈识别出六个主题,参与者描述了2010年以来系统内的改进和显著创新。
- 创新包括建立使用短信调查的主动队列事件监测系统。
- 专家认为澳大利亚具备新冠疫苗安全监测的良好基础。
- 新冠免疫规划实施被视为通过改进主动监测与自发报告整合、发展数据链接的人群主动监测来持续增强系统的潜在驱动力。
- 透明沟通被认为对应对新冠前所未有的挑战和更广泛的疫苗安全关切至关重要。
临床怎么用
- 疫苗药物警戒应结合主动监测与自发报告系统,并探索数据链接实现人群层面主动监测。
- 透明沟通是应对疫苗安全关切和新发传染病免疫规划挑战的关键要素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In 2010, the Australian seasonal influenza vaccination program for children under 5 years of age was suspended due to an unexpected increase in fever and febrile convulsions causally associated with one particular influenza vaccine brand. A subsequent national review made seven recommendations to improve vaccine pharmacovigilance. Ten years on, in advance of implementing the COVID-19 immunisation program, we evaluated views on the capacity of Australia's vaccine pharmacovigilance system to promptly detect, examine and communicate a signal. METHODS: Semi-structured interviews were conducted between July and October 2020 with individuals with expertise in vaccine safety in Australia using an interview guide informed by key Australian and international frameworks. Interviews were digitally recorded and transcribed verbatim. Thematic analysis was used to code data using a deductive approach. RESULTS: Interviews with seventeen participants enabled six themes to be identified. Participants described improvement and significant innovation within Australia's vaccine pharmacovigilance system over the decade since 2010, particularly through establishment of a new active, cohort event monitoring system using short message service surveys. Participants thought Australia had a good foundation for COVID-19 vaccine safety surveillance; implementation of the COVID-19 immunisation program was seen as a potential driver for ongoing enhancement through: a) improved integration of the active surveillance and spontaneous reporting systems, and; b) development of population-level active surveillance, including through data linkage. Transparent communication was considered essential to address the unprecedented challenges of COVID-19 and broader vaccine safety concerns. CONCLUSIONS: Vaccine safety experts in Australia convey confidence in the innovative pharmacovigilance systems implemented over the past 10 years. While Australia has a multifaceted system incorporating both active surveillance and spontaneous reporting systems, COVID-19 vaccine implementation represents an opportunity to enhance current systems and to develop new, systematic approaches to vaccine pharmacovigilance that should make both a local and global contribution.
引用
- Phillips A, Carlson S, Danchin M, et al. From program suspension to the pandemic: A qualitative examination of Australia's vaccine pharmacovigilance system over 10 years. Vaccine. 2021. PMID: 34376308. doi:10.1016/j.vaccine.2021.07.059
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。